NRX-100 + NRX-101

**NRX-100 + NRX-101** refers to a two-step regimen developed for the treatment of severe bipolar depression with suicidality. \n- **NRX-100** is preserved-free intravenous ketamine, used for rapid stabilization of patients with acute suicidal ideation or behavior. Ketamine is an NMDA (N-methyl-D-aspartate) receptor antagonist, providing rapid relief from suicidality and depressive symptoms when administered in a controlled, clinical setting[2][6][11][12]. \n- **NRX-101** is a patented, oral, fixed-dose combination of D-cycloserine (an NMDA receptor modulator/antagonist at therapeutic doses) and lurasidone (a 5-HT2a serotonin receptor antagonist/antipsychotic)[1][2][3][7]. NRX-101 is intended to maintain the improvement gained after ketamine stabilization, reducing the chance of relapse in depression and suicidality by continued, non-sedating, non-psychedelic therapy in the outpatient setting. \nThis sequential regimen was specifically designed to address the need for both acute and maintenance treatment in suicidal bipolar depression, with NRX-101 providing a superior safety profile in terms of akathisia risk while maintaining efficacy[4][5][7].